The Largest European Drug Discovery Meeting Held this Month
News Oct 18, 2007
The EMCC was completely full for the duration of the ELRIG/SBS meeting which took place recently in Nottingham. This was the largest Drug Discovery meeting held in Europe through 2007.
With 6 tracks over 2 days and in excess of 750 delegates registered, all of the sessions were full, some with standing room only. The audiences were treated to 43 industry leaders giving presentations on a variety of topics including:
*Assay Development for HTS and SAR
*The Challenges of Sample Management
*Automated Electrophysiology and Ion Channel Drug Screening
*Strategies for the Design and use of High Throughput Automation
*Cell and Protein Supply for HTS and SAR
*GPCRs:Addressing Novel Pharmacologies in the HTS Environment
Plus two Keynote speakers, Bob Hertzberg, GSK, opening on Day 1 and Chris Lipinski, Melior Discovery, closing on Day 2. They discussed the history and benefits of automation within Drug Discovery and the challenges facing the industry.
As ELRIG had taken over the whole venue, every room was allocated to varying industry items relating to the event. ELRIG also ran a range of Training Courses which the delegates could attend free of charge.
The Training is a prominent feature of all ELRIG meetings and is proving to be extremely popular.
Over 53 vendor companies attended the show, all reporting that this meeting helped to generate excellent leads and were very satisfied with the amount of delegates that visited their stands.
Over 50 high quality Posters were received which complemented the podium presentations. A lively drinks reception marked the end of Day 1 where Feedback Survey Form Prize Draw also took place.
Andy Tee of Pfizer was presented with a Satellite Navigation system.
CerionX won Champagne for the ‘Most Innovative New Technology.’
At the end of Day 2 the second Prize Draw took place and this time:-
1. Sheila McLoughlin of UCB won the Satellite Navigation system.
2. SpinX received Champagne for the ‘Most Innovative New Technology.’
Some MRSA infections could be tackled using widely-available antibiotics, suggests new research. A team of scientists used genome sequencing technology to identify which genes make MRSA susceptible to a previously defined combination of drugs. They identified a number of mutations centered around a protein known as a penicillin-binding protein 2a or PBP2a.